Abstract
DuPont de Nemours Inc will report first‑quarter 2026 results on May 5, 2026 Pre-Market, with consensus pointing to a step-down in revenue and earnings as post‑separation comparisons reset and investors watch for early‑year demand and currency tailwinds.Market Forecast
Consensus for the current quarter anticipates revenue of 1.67 billion US dollars, representing a year‑over‑year decrease of 45.23%, EBIT of 304.51 million US dollars (down 49.69% year‑over‑year), and adjusted EPS of 0.48 US dollars (down 49.23% year‑over‑year). Management has indicated first‑quarter 2026 net sales should benefit from roughly 2% organic growth and a 2% currency tailwind versus the prior year, while not specifying margins or EPS; margin guidance has not been provided and will be inferred from mix, pricing, and cost‑savings progress at the print.The company’s revenue mix last quarter was anchored by Diversified Industries at 872.00 million US dollars and Healthcare & Water Technologies at 821.00 million US dollars; management commentary and analyst previews suggest Healthcare & Water could see relatively firmer demand, while construction‑exposed end uses remain a swing factor. Within that mix, the most promising segment into mid‑year remains Healthcare & Water Technologies given consistent order patterns and early‑year currency support; its last‑quarter revenue base was 821.00 million US dollars, with year‑over‑year growth for the segment not specified by the company, though company‑level year‑over‑year growth drivers imply modest positive organic contribution in the current quarter.
Last Quarter Review
In the prior quarter, DuPont de Nemours Inc posted revenue of 1.69 billion US dollars (down 45.25% year‑over‑year), a GAAP net loss attributable to shareholders of 126.00 million US dollars, an implied net profit margin of approximately -7.44%, and adjusted EPS of 0.46 US dollars (down 59.29% year‑over‑year); gross profit margin was not disclosed in the available dataset. A key financial highlight was operating EBITDA of 409.00 million US dollars alongside positive transaction‑adjusted free cash flow of 228.00 million US dollars, while GAAP results reflected separation‑related costs. By business line, the quarter’s revenue composition featured Diversified Industries at 872.00 million US dollars and Healthcare & Water Technologies at 821.00 million US dollars; segment‑level year‑over‑year trends were not specified, while overall company revenue declined year‑over‑year.Current Quarter Outlook
Core earnings trajectory and revenue mix
The near‑term setup reflects a quarter defined by reset comparisons and portfolio actions rather than broad‑based cyclical acceleration. With revenue anticipated at 1.67 billion US dollars and adjusted EPS near 0.48 US dollars, consensus embeds a pronounced year‑over‑year contraction against a re‑based portfolio, along with modest volume recovery that is not yet strong enough to offset last year’s headwinds. Management’s signpost of roughly 2% organic growth augmented by a 2% currency tailwind suggests the top line could see incremental support from pricing and FX, but not enough to override the structural step‑down already reflected in external estimates. Mix will matter: exposure to steadier healthcare and water markets should lend ballast to margins, while construction and other industrial demand remain the swing variables for volumes and utilization.On profitability, investors will look to EBIT of roughly 304.51 million US dollars as a proxy for operating progress. The gap between EBIT and adjusted EPS expectations implies that, while cost discipline and self‑help measures are continuing, deleveraging on a smaller revenue base and transitional separation costs are still weighing on year‑over‑year comparisons. Gross margin was not guided, but margin direction will be heavily influenced by product mix toward higher‑value consumables and filtration, realized pricing, and procurement savings. Any evidence of improved throughput or lower input costs would help close the gap between implied margins and medium‑term targets communicated around the separation process.
Cash conversion is another focal point. The prior quarter delivered positive transaction‑adjusted free cash flow even amid GAAP charges, an encouraging signal as the company continues to streamline its footprint and refocus capital allocation. For this quarter, watch for working‑capital normalization after year‑end activity, especially within receivables and inventories tied to healthcare and water applications. The interplay between modest organic growth, a supportive currency backdrop, and tight expense control will likely determine whether cash generation tracks with seasonal norms despite reduced sales.
Healthcare & Water Technologies
Healthcare & Water Technologies, with last‑quarter revenue of 821.00 million US dollars, stands out as the segment most likely to provide resilience this quarter. Management commentary and external previews point to favorable demand trends in water solutions and stable healthcare‑related consumables and components. The company’s indication of low single‑digit organic growth combined with an FX tailwind provides a constructive backdrop for this segment’s top line, particularly where orders are tied to secular replacement and efficiency needs rather than discretionary projects. Because these end uses tend to carry relatively attractive margins, even small lifts in volume can be disproportionately supportive of EBIT and EPS at the current revenue base.From a margin perspective, this segment benefits from product categories where pricing pass‑throughs and value‑added attributes are stickier than in more commoditized markets. The critical watch items are order cadence and backlog health through the first two months of the quarter, as well as any commentary on lead times or fulfillment constraints that might limit revenue recognition. Given that the prior quarter’s GAAP loss reflected separation‑related items, current‑quarter segment performance will be viewed through the lens of “clean” run‑rate earnings power. Delivery against internal cost‑reduction milestones in this segment could provide an incremental earnings bridge even if volumes only match management’s modest growth expectation.
Currency is a tangible variable for this segment as well. With management flagging a roughly 2% tailwind from FX at the company level, multinational exposures within water and healthcare could see translation benefits. Investors will be listening for whether realized pricing and favorable FX together can offset any lingering mix headwinds within the portfolio. A stable or slightly improving trajectory here would help validate the bullish institutional stance that highlights this segment’s role in underpinning overall earnings quality.
Portfolio actions, capital structure, and stock price drivers
Two corporate actions frame the investment narrative into this print and the early part of the second quarter. On April 1, 2026, the company completed the sale of its Aramids business for a transaction value of about 1.80 billion US dollars, receiving approximately 1.20 billion US dollars in pre‑tax cash proceeds, a 300.00 million US dollar note receivable, and roughly a 16% equity interest in the buyer valued at 325.00 million US dollars. While the benefit of those proceeds is primarily a capital allocation and balance‑sheet consideration, the deal also simplifies the ongoing earnings base, making mix within the remaining operations more transparent. In a separate step, the company is seeking shareholder approval for a reverse stock split (range 1‑for‑2 to 1‑for‑4), which, if implemented, would adjust share count optics without altering intrinsic value; the board retains discretion on timing or cancellation. Neither action directly affects first‑quarter operating revenue, but both inform investor expectations for capital deployment, EPS construct, and valuation.Against this backdrop, the stock’s reaction will likely be driven by four levers at the print. First, the revenue outcome relative to the 1.67 billion US‑dollar consensus amid the 2% organic and 2% FX management signals. Second, the quality of margins, where evidence of procurement savings, mix toward healthcare and water, and disciplined SG&A could allow EBIT to meet or exceed the 304.51 million US‑dollar bar. Third, the trajectory of GAAP items versus adjusted measures, given that separation and restructuring activities weighed on the prior quarter’s GAAP net loss; a narrower GAAP/adjusted gap would be taken positively. Fourth, cash‑flow discipline and commentary on proceeds redeployment following the Aramids transaction, including potential debt actions, share repurchases, or reinvestment to accelerate growth in core platforms.
Finally, the shape of the second‑quarter exit rate is crucial. Even if first‑quarter figures align with subdued year‑over‑year comps, investors will be particularly attentive to order trends and backlog conversion that point to smoother seasonal improvements. Clarity on the cadence of any construction‑exposed demand recovery will help stabilize forward estimates. Conversely, if pricing, volume, or FX benefits undershoot expectations in the current quarter, the market may revisit trajectory assumptions for earnings re‑acceleration in the back half.
Analyst Opinions
Analyst sentiment in the year‑to‑date period is skewed bullish, with the majority of published views tilting positive; among perspectives gathered from January 2026 through April 2026, five large‑cap brokers maintain Buy or Outperform recommendations, and one maintains a Neutral/Equal‑Weight stance, implying roughly an 83% bullish skew. The positive camp emphasizes improved earnings quality after portfolio simplification, resilient demand within healthcare and water, and the capacity for free cash flow to fund shareholder returns and targeted reinvestment.- RBC Capital maintained an Outperform rating and adjusted its price target to 56 US dollars in late April while reiterating a constructive earnings‑growth framework predicated on disciplined capital stewardship and exposure to growth within water and healthcare. The firm’s stance highlights an expected 8%–10% earnings growth algorithm before buybacks in the years ahead, contingent on moderate industrial recovery and steady execution.
- Citigroup reiterated a Buy rating in mid‑April with a 56 US‑dollar target, underscoring the company’s reset portfolio and potential for operating leverage as mix shifts toward higher‑value platforms. Citi’s view aligns with the premise that modest volume growth, continued cost actions, and disciplined deployment of recent divestiture proceeds can underpin the earnings bridge embedded in consensus.
- Jefferies maintained a Buy rating (target 59 US dollars), reflecting confidence that the consolidated portfolio can sustain durable free‑cash‑flow generation and benefit from smoother demand in core end markets. The emphasis is on execution: a clean sequential setup, improved productivity, and mix favoring higher‑margin categories to protect EBIT and EPS through cyclical noise.
- UBS kept a Buy rating with a 49 US‑dollar target in late January, focusing on visibility into mid‑cycle earnings power and valuation support as the company navigates separation‑related transitions. UBS’s work suggests the risk/reward remains favorable provided first‑quarter results confirm the direction of organic growth and currency tailwinds.
- Morgan Stanley remains Neutral/Equal‑Weight, but raised its price target to 52 US dollars following the February update, citing constructive trends in water and healthcare while acknowledging construction markets as a key swing factor; its 2026 and 2027 EPS forecasts were lifted above prior estimates. The neutral stance reflects a preference to see clearer evidence that margin progress and volume recovery can outpace recalibrated expectations through mid‑year.
The majority‑bullish interpretation of these views is straightforward. First, analysts broadly anticipate that the re‑based first‑quarter setup—with consensus revenue near 1.67 billion US dollars and EPS near 0.48 US dollars—captures the lion’s share of structural step‑downs, setting a more achievable bar for subsequent improvement. Second, Healthcare & Water Technologies is widely cited as the anchor for stability, with early‑year pricing and FX tailwinds supporting a steady revenue cadence and helping to protect margins. Third, capital structure moves, including the completed Aramids sale and the contemplated reverse split, enhance strategic flexibility and sharpen the earnings narrative, improving confidence in free‑cash‑flow deployment without diluting focus on operational execution.
Within that framework, the bull case into this print centers on confirmation of incremental positives rather than a rapid acceleration. Delivery in line or slightly ahead of the 1.67 billion US‑dollar revenue and 0.48 US‑dollar EPS marks—accompanied by commentary that validates low single‑digit organic growth plus translation benefits—would likely keep upward pressure on medium‑term estimates. Evidence that procurement, productivity, and mix are translating into margin resilience would further support Buy‑side theses. Conversely, misses tied to construction‑exposed weakness or an absence of margin progress would not overturn the majority view but could delay timing expectations for re‑acceleration.
Overall, the preponderance of institutional commentary points to constructive expectations into the first quarter, grounded in a cleaner portfolio, steadier end‑market exposure within healthcare and water, and a clearer balance‑sheet pathway after recent divestiture activity. With consensus already embedding sizable year‑over‑year declines, the burden of proof is to demonstrate incremental momentum and confirm that the second quarter begins with a healthier order book and margin baseline. If those signals are present, the majority of analysts appear prepared to maintain or strengthen favorable recommendations as the year progresses.
Comments